Unveiling ETX-148's Promise in Bleeding Disorders
e-therapeutics plc is poised to present exciting new preclinical data on its innovative drug candidate, ETX-148, at a prestigious international conference. This event, the Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), offers a notable platform for sharing advancements in treatment approaches for bleeding disorders, specifically haemophilia A and B. The research elucidates the efficacy and safety of ETX-148, marking a significant development in the landscape of RNAi-based therapeutics.
Details of the Upcoming Presentation
During the congress, e-therapeutics will conduct an oral presentation highlighting the results from murine models demonstrating ETX-148's capabilities in combatting haemophilia. Here are some specifics regarding the session:
Presentation Title
The presentation is titled "Efficacy and Safety of ETX-148 in Murine Models of Haemophilia A and B," showcasing groundbreaking data and insights.
Session Information
This significant presentation is scheduled for the 7th of February. It will be part of the SLAM session, providing a great opportunity for expert dialogue and discussion in the realm of bleeding disorders.
About e-therapeutics plc
e-therapeutics plc, often referred to as ETX, is at the forefront of integrating computational biology with RNA interference (RNAi) technologies to devise life-changing therapeutics. The company's proprietary platform, GalOmic™, is engineered to develop specific and potent small interfering RNA (siRNA) therapeutics, targeting novel gene expressions effectively, particularly in liver cells, known as hepatocytes.
Innovative Platforms Driving Drug Discovery
ETX employs its advanced HepNet™ computational platform, which is pivotal in accelerating the drug development process. This platform enhances the drug discovery pipeline through extensive knowledge databases and AI-driven methodologies, enabling the identification of promising gene targets much more efficiently.
Collaboration and Validation
The credibility of e-therapeutics' approaches is supported by successful collaborations with notable biopharma entities, including Novo Nordisk, Galapagos NV, and iTeos Therapeutics. The interactions have provided critical insights and data that solidify ETX's stronghold in the application of computational strategies in biomedical research.
Progressing Towards Clinical Applications
With the leveraging capabilities of GalOmic™ and HepNet™, e-therapeutics is advancing a compelling pipeline of RNAi therapies aimed at various critical medical conditions that currently lack adequate treatments. In particular, the company has shown promising proof-of-concept data in addressing disorders such as metabolic dysfunction-associated steatohepatitis (MASH), dry age-related macular degeneration (dry AMD), haemophilia, heart failure, and other cardiometabolic challenges.
Current Pipeline of Therapeutics
Among its most promising candidates are ETX-312, meant for MASH; ETX-148, targeting bleeding disorders; and ETX-407, which is designed for treating dry AMD. Each of these assets is making significant strides towards the investigational new drug (IND) enabling stages, laying the groundwork for potential clinical trials by 2026 and beyond.
Contact Information
For inquiries, please reach out via:
Press Contact
press@etherapeutics.co.uk
Investor Relations Contact
investorrelations@etherapeutics.co.uk
Frequently Asked Questions
What is ETX-148?
ETX-148 is a drug candidate being developed by e-therapeutics for the treatment of bleeding disorders, particularly haemophilia A and B.
Where will e-therapeutics be presenting its data?
The company will present its preclinical data at the Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD).
What are the core platforms used by e-therapeutics?
e-therapeutics utilizes the GalOmic™ and HepNet™ platforms to enhance the discovery and development of RNAi therapeutics.
Who are some of e-therapeutics' collaborators?
ETX collaborates with prominent biopharma companies such as Novo Nordisk, Galapagos NV, and iTeos Therapeutics.
What are the primary disorders targeted by e-therapeutics' research?
The company targets various disorders, including metabolic dysfunction, age-related macular degeneration, and bleeding disorders like haemophilia.
